Literature DB >> 21717526

Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.

Cristina R Antonescu1, Lei Zhang, G Petur Nielsen, Andrew E Rosenberg, Paola Dal Cin, Christopher D M Fletcher.   

Abstract

Despite their shared predilection for superficial soft tissue of distal extremities and frequent local recurrences, myxoinflammatory fibroblastic sarcoma (MIFS) and hemosiderotic fibrolipomatous tumor (HFLT) have distinct morphologic appearances. Recent studies have identified an identical t(1;10)(p22;q24) in five cases of MIFS and two of HFLT, as well as common amplifications on 3p11-12. To investigate further their potential relationship and to determine the incidence of t(1;10) in a larger cohort, we subjected seven MIFS, 14 HFLT, and three cases with mixed morphology, to molecular and cytogenetic analysis. Fluorescence in situ hybridization (FISH) analysis for rearrangements of TGFBR3 on 1p22 and of MGEA5 on 10q24 was performed in all cases, whereas the status of VGLL3 gene amplification on 3p12.1 was investigated in 12 cases. Conventional karyotyping was performed in one HFLT and two cases with mixed MIFS/HFLT histology. Overall 83% of cases showed rearrangements in both TGFBR3 and MGEA5. All three cases with mixed features of MIFS and HFLT were positive. Cytogenetic analysis performed in three cases confirmed an unbalanced der(10)t(1;10)(p22;q24). VGLL3 gene amplification was noted in 10/12 cases of both histologies. The high incidence of t(1;10) in MIFS and HFLT reinforces a shared pathogenetic relationship. Furthermore, the co-existence of both components either synchronously or metachronously in a primary or subsequent recurrence, suggest either different morphologic variants or different levels of tumor progression of a single biologic entity. FISH analysis for TGFBR3 and MGEA5 rearrangements can be applied as a reliable diagnostic molecular test when confronted with limited material or a challenging diagnosis.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717526      PMCID: PMC3361892          DOI: 10.1002/gcc.20897

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  22 in total

1.  Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link.

Authors:  Christopher P Elco; Adrián Mariño-Enríquez; John A Abraham; Paola Dal Cin; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

2.  Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8.

Authors:  Maija P Valta; Teuvo Hentunen; Qiang Qu; Eeva M Valve; Anna Harjula; Jani A Seppänen; H Kalervo Väänänen; Pirkko L Härkönen
Journal:  Endocrinology       Date:  2006-01-26       Impact factor: 4.736

3.  Hemosiderotic fibrohistiocytic lipomatous lesion: ten cases of a previously undescribed fatty lesion of the foot/ankle.

Authors:  C Marshall-Taylor; J C Fanburg-Smith
Journal:  Mod Pathol       Date:  2000-11       Impact factor: 7.842

4.  Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes.

Authors:  I Lambert; M Debiec-Rychter; P Guelinckx; A Hagemeijer; R Sciot
Journal:  Virchows Arch       Date:  2001-05       Impact factor: 4.064

5.  EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene.

Authors:  Cristina R Antonescu; Lei Zhang; Ning-En Chang; Bruce R Pawel; William Travis; Nora Katabi; Morris Edelman; Andrew E Rosenberg; G Petur Nielsen; Paola Dal Cin; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

6.  YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas.

Authors:  Zofia Hélias-Rodzewicz; Gaëlle Pérot; Frédéric Chibon; Céline Ferreira; Pauline Lagarde; Philippe Terrier; Jean-Michel Coindre; Alain Aurias
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

7.  Early pleomorphic hyalinizing angiectatic tumor: precursor or distinct lesion?

Authors:  Vincent M Moretti; Michael de la Cruz; John S J Brooks; Richard D Lackman
Journal:  Orthopedics       Date:  2010-07-13       Impact factor: 1.390

8.  Haemosiderotic fibrolipomatous tumour (so-called haemosiderotic fibrohistiocytic lipomatous tumour): analysis of 13 new cases in support of a distinct entity.

Authors:  T-J Browne; C D M Fletcher
Journal:  Histopathology       Date:  2006-03       Impact factor: 5.087

9.  Cytogenetic analysis of a hemosiderotic fibrolipomatous tumor.

Authors:  George R Wettach; Luke J Boyd; Helen J Lawce; R Ellen Magenis; Atiya Mansoor
Journal:  Cancer Genet Cytogenet       Date:  2008-04-15

10.  Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions.

Authors:  Karolin H Hallor; Raf Sciot; Johan Staaf; Markus Heidenblad; Anders Rydholm; Henrik Cf Bauer; Kristina Aström; Henryk A Domanski; Jeanne M Meis; Lars-Gunnar Kindblom; Ioannis Panagopoulos; Nils Mandahl; Fredrik Mertens
Journal:  J Pathol       Date:  2009-04       Impact factor: 7.996

View more
  22 in total

1.  Pleomorphic hyalinizing angiectatic tumor: imaging findings.

Authors:  Ty K Subhawong; Andrea P Subhawong; Elizabeth A Montgomery; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2012-06-03       Impact factor: 2.199

2.  Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome.

Authors:  William B Laskin; John F Fetsch; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

Review 3.  From vestigial to vestigial-like: the Drosophila gene that has taken wing.

Authors:  Emilie Simon; Corinne Faucheux; Alain Zider; Nadine Thézé; Pierre Thiébaud
Journal:  Dev Genes Evol       Date:  2016-04-26       Impact factor: 0.900

4.  Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.

Authors:  Yu-Chien Kao; Valentina Ranucci; Lei Zhang; Yun-Shao Sung; Edward A Athanasian; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

5.  Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.

Authors:  Naoto Hori; Kazuyuki Okada; Yuki Takakura; Hiroyuki Takano; Naoto Yamaguchi; Noritaka Yamaguchi
Journal:  J Biol Chem       Date:  2020-05-08       Impact factor: 5.157

6.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

7.  A genetic dichotomy between pure sclerosing epithelioid fibrosarcoma (SEF) and hybrid SEF/low-grade fibromyxoid sarcoma: a pathologic and molecular study of 18 cases.

Authors:  Carlos Prieto-Granada; Lei Zhang; Hsiao-Wei Chen; Yun-Shao Sung; Narasimhan P Agaram; Achim A Jungbluth; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-09-18       Impact factor: 5.006

Review 8.  VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs.

Authors:  Xiaochong Deng; Lin Fang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

9.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

10.  Plexiform fibrohistiocytic tumor: imaging features and clinical findings.

Authors:  Marcus Ghuman; Sinchun Hwang; Cristina R Antonescu; David M Panicek
Journal:  Skeletal Radiol       Date:  2018-08-25       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.